Literature DB >> 24401900

Pathophysiology of anemia in chronic kidney diseases: A review.

Josef Zadrazil1, Pavel Horak1.   

Abstract

UNLABELLED: Backgroud. Anemia is one of the laboratory and clinical findings of chronic kidney diseases (CKD). The presence of anemia in patients with CKD has a wide range of clinically important consequences. Some of the symptoms that were previously attributed to reduced renal function are, in fact, a consequence of anemia. Anemia contributes to increased cardiac output, the development of left ventricular hypertrophy, angina, and congestive heart failure. According to current knowledge, anemia also contributes to the progression of CKD and is one of the factors that contribute to the high morbidity and mortality in patients with chronic renal failure and their reduced survival.
METHODS: MEDLINE search was performed to collect both original and review articles addressing anemia in CKD, pathophysiology of renal anemia, erythropoiesis, erythropoietin, iron metabolism, inflammation, malnutrition, drugs, renal replacement therapy and anemia management
CONCLUSION: The present review summarized current knowledge in the field of the pathophysiology of renel anemia. Understanding the pathophysiology of anemia in CKD is crucial for the optimal treatment of anemia according to recent clinical practice guidelines and recommendation, and correct recognition of causes of resistence to treatment of erythropoietin stimulating agents (ESA).

Entities:  

Keywords:  anemia; chronic kidney diseases; erythropoiesis; erythropoietin; irone metabolism

Mesh:

Substances:

Year:  2014        PMID: 24401900     DOI: 10.5507/bp.2013.093

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  10 in total

1.  Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis.

Authors:  Pei Yin; Yan Song; Jijun Li
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

2.  Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.

Authors:  Steven Fishbane; Bhupinder Singh; Seema Kumbhat; Wayne A Wisemandle; Nancy E Martin
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-19       Impact factor: 8.237

3.  α-klotho and anemia in patients with chronic kidney disease patients: A new perspective.

Authors:  Yang Xu; Hao Peng; Ben Ke
Journal:  Exp Ther Med       Date:  2017-10-11       Impact factor: 2.447

4.  Gallbladder Visualization on Tc-99m-labeled Red Cell Scintigraphy: A Rare Finding with an Emphasis on Role of Single-photon Emission Computed Tomography/Computed Tomography.

Authors:  Narvesh Kumar; Rani Kunti Randhir Singh; Deepanksha Dutta; Mudalsha Ravina; Subhash Chand Kheruka; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2017 Jul-Sep

5.  Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease.

Authors:  Steven Fishbane; Bruce S Spinowitz; Wayne A Wisemandle; Nancy E Martin
Journal:  Kidney Int Rep       Date:  2019-05-22

6.  Bilateral Optic Atrophy in a Young Patient With Chronic Anaemia Secondary to End-Stage Renal Disease.

Authors:  Nor Hasnida Ab Gani; Mohtar Ibrahim; Wan-Hazabbah Wan Hitam; Nurul Ain Masnon; Amirah Hassan
Journal:  Cureus       Date:  2021-03-18

7.  Correlation between Physical Activity and Psychological Distress in Patients Receiving Hemodialysis with Comorbidities: A Cross-Sectional Study.

Authors:  Yu-Hui Wu; Yu-Juei Hsu; Wen-Chii Tzeng
Journal:  Int J Environ Res Public Health       Date:  2022-03-26       Impact factor: 3.390

8.  Frequency of Specific Cardiovascular Disease Risk Factors among Cameroonian Patients on Dialysis: The Cases of Anaemia, Inflammation, Phosphate, and Calcium.

Authors:  Olivier Pancha Mbouemboue; Olivier Djile Danbe; Marcel Tangyi Tamanji; Jacques Olivier Ngoufack
Journal:  Cardiol Res Pract       Date:  2016-05-22       Impact factor: 1.866

9.  Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies.

Authors:  Jay B Wish; Marcelo G Rocha; Nancy E Martin; Christian Russel D Reyes; Steven Fishbane; Mark T Smith; George Nassar
Journal:  Kidney Med       Date:  2019-08-28

Review 10.  The Influence of Inflammation on Anemia in CKD Patients.

Authors:  Anna Gluba-Brzózka; Beata Franczyk; Robert Olszewski; Jacek Rysz
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.